Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | TNF | P01375 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060938 | 0.89 | KMT2A (0.51) | SLC17A5MDM4TP53CASP1CASP3 | |
| SCHEMBL29456972 | 0.88 | SLC17A5 (0.51) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL31398346 | 0.88 | MDM2 (0.51) | MDM4TP53CASP1TLR2CASP3 | |
| SCHEMBL31398353 | 0.88 | MDM2 (0.51) | MDM4TP53CASP1TLR2CASP3 | |
| SCHEMBL25358998 | 0.88 | MDM2 (0.51) | MDM4TP53CASP1TLR2CASP3 | |
| SCHEMBL29407853 | 0.88 | MDM4 (0.51) | SLC17A5MDM4TP53CASP1TLR2 | |
| SCHEMBL119481 | 0.88 | MDM4 (0.51) | SLC17A5MDM4TP53CASP1TLR2 | |
| SCHEMBL30055069 | 0.88 | MDM4 (0.51) | SLC17A5MDM4TP53CASP1TLR2 | |
| SCHEMBL29376536 | 0.88 | MDM4 (0.51) | SLC17A5MDM4TP53CASP1TLR2 | |
| SCHEMBL178741 | 0.88 | MDM4 (0.51) | SLC17A5MDM4TP53CASP1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| EP-3988170-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | SLC17A5 1079/4885MDM4 4731/4885TP53 4462/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | SLC17A5 1130/4885MDM4 4725/4885TP53 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.